Uncover key drivers, emerging technologies, and competitive movements shaping the biologic & biosimilar ra drugs market from 2025–2034 with trusted insights from The Business Research Company
What Is The Predicted Size Of The Biologic & Biosimilar RA Drugs Industry By 2029?
The biologic & biosimilar ra drugs market size has shown consistent expansion in recent years. It is anticipated to increase from $13.99 billion in 2024 to $14.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. Historically, this growth has been influenced by elements such as market adoption rates, outcomes of clinical trials, shifts in market share, long-term patient outcomes, and pricing strategies.
The market for biologic & biosimilar RA drugs is projected to experience substantial expansion in the upcoming years. This market is anticipated to reach a valuation of $19.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.0%. This projected growth during the forecast period is attributable to factors such as the rise in biologic drug development, intensified market competition, evolving healthcare policies, shifts in patient preferences, and ongoing clinical research & development. Key trends anticipated within this forecast timeframe encompass an escalation in biosimilar market competition, the emergence of personalized medicine and precision therapy, continuous advancements in drug delivery systems, a heightened emphasis on safety and efficacy, and a move towards patient-centric healthcare approaches.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What Major Drivers Are Impacting The Biologic & Biosimilar RA Drugs Market?
The growth in the elderly demographic and the escalating prevalence of rheumatoid arthritis are propelling the biologics and biosimilar RA drugs market. The term “older population” specifically denotes individuals aged 60 years or more. Rheumatoid arthritis (RA) is an autoimmune disorder where an individual’s immune system mistakenly attacks healthy cells, primarily impacting their joints. This condition disproportionately affects the elderly, given that the immune system naturally weakens with advancing age. In treating rheumatoid arthritis, biologics and biosimilar RA drugs offer significant advantages over traditional medications. For example, data from the World Health Organization (WHO), a UN specialized health agency located in Switzerland, indicates that approximately 1 billion people worldwide were 60 or older in 2020, with projections for this group to expand to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention (CDC), a US governmental public health agency, forecasts that the count of adults with arthritis in the USA will rise to 78.4 million by 2040, alongside an estimated 34.6 million individuals experiencing activity limitations due to arthritis. Consequently, the combination of a growing senior population and a rise in RA diagnoses is significantly boosting the biologics and biosimilars RA drugs market.
Which Segment Categories Are Driving Maximum Growth In The Biologic & Biosimilar RA Drugs Market?
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Which Long-Term Trends Will Play A Crucial Role In The Biologic & Biosimilar RA Drugs Market?
Novel advancements represent a significant and growing trend within the biologic & biosimilar RA drugs market. Leading companies in the biologic & biosimilar RA drugs market are concentrating their efforts on creating biosimilar therapies, including Dual Concentration Biosimilar Options, to offer more economical choices. An example of this is the July 2023 launch of HADLIMA, a Humira (adalimumab) biosimilar, in the US by Organon, a US-based healthcare firm, and Samsung Bioepis, a South Korea-based biopharmaceutical firm. HADLIMA, offered in both high and low concentrations, is designed to improve accessibility and lower costs for individuals suffering from autoimmune conditions. This biosimilar carries an 85% discount compared to Humira, thereby broadening patient reach. Furthermore, HADLIMA features an autoinjector, endorsed by the Arthritis Foundation, alongside a patient support initiative named HADLIMA For You, which provides educational materials and co-payment assistance. Its indications span multiple conditions, such as rheumatoid arthritis and Crohn’s disease. HADLIMA is provided in both a citrate-free high concentration (100 mg/mL) and a citrate-containing low concentration (50 mg/mL), ensuring continuous and uninterrupted care for patients.
Who Are The Dominant Players In The Biologic & Biosimilar RA Drugs Market Today?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Download The Full Report Here:
Which Region Is At The Forefront Of Innovation In The Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2025, By The Business Research Company
Cardiovascular Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Dermatology Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Gastrointestinal Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model